Under the contracts BioClinica will support several hundred clinical studies annually through 2017 with two unnamed top 10 pharma clients.
In the first agreement BioClinica will provide resources and subject matter expertise in clinical supply chain distribution systems and processes that extend to several thousand investigators using its Interactive Response Technology.
In the second agreement, BioClinica's OnPoint CTMS and Express EDC technologies will provide the foundation for a sponsor’s clinical operations. Data management, study design, and related professional services that support clinical studies globally will also be provided.
BioClinica's President of eClinical Solutions Peter Benton told Outsourcing-Pharma.com. "We continue to see an increase in new customers and larger awards as customers learn about our approach to clinical trial management solutions.
“There are many players in this space with varying levels of service and a wide range of prices. We’ve had new customers come to us with stories of 300% price increases for the same product they purchased years ago – without significant improvements.”
The contracts extend partnering arrangements that originated a decade ago. Since then, BioClinica has supported the two organizations in clinical trials across thousands of investigative sites worldwide.
BioClinica technologies create efficiencies that can compress clinical investigation timelines by weeks.
"We think there are plenty of pharmaceutical companies and CROs that can benefit from eClinical solutions and run faster, more efficient clinical trials,” Benton told us. “The recent contracts we announced were with existing customers, but the renewals went through a competitive process. That is very gratifying, as it shows that customers like the results they get from BioClinica when compared to the promises of other vendors. Price matters, but only if there is value and service.”
Enterprise-wide implementation of cloud-based technologies is currently underway with BioClinica employees contracted to be embedded within each organization, augmenting the pharmaceutical companies' internal resources.